Skip to main content
2023 IKCS: North America Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Top Papers of 2023 & Discussion

Saturday, November 11, 2023
2:20 PM – 2:50 PM CST
Location: Legends ABCD

    Moderator(s)

  • Stephanie A. Berg, DO

    Dana-Farber Cancer Institute
    Needham, MA, United States

    Disclosure(s): No financial relationships to disclose

    • Panelist(s)

  • Arpita Desai, MD

    University of California San Francisco
    UCSF, California, United States

    Disclosure(s): Contract Research: Merck (Ongoing)
    Participated in Advisory board on 7/12/23: Exelixis (Terminated, July 12, 2023)
    Participated in Advisory board on 7/20/22: Merck (Terminated, July 20, 2022)

    Slides

  • Daniel Shapiro, MD

    University of Wisconsin-Madison

    Disclosure(s): No financial relationships to disclose

    Slides

  • Hong Truong, MD

    Penn State University College of Medicine
    Penn State University College of Medicine, Pennsylvania, United States

    Disclosure(s): No financial relationships to disclose

    Slides

  • Laurence Albiges, MD, PhD

    Institut Gustave Roussy
    VILLEJUIF, Ile-de-France, France

    Disclosure(s): Advisory or Consulting or Honoraria, (all paid to Institution): Astellas – BMS – Ipsen – Janssen – Merck - MSD – Novartis - Pfizer – EISAI – Roche (Ongoing)

  • Dena Battle

    KCCure
    KCCure

    Disclosure information not submitted.

Disclosure(s):
Stephanie A. Berg, DO: No financial relationships to disclose
Arpita Desai, MD: Contract Research: Merck (Ongoing)
Participated in Advisory board on 7/12/23: Exelixis (Terminated, July 12, 2023)
Participated in Advisory board on 7/20/22: Merck (Terminated, July 20, 2022)
Daniel Shapiro, MD: No financial relationships to disclose
Hong Truong, MD: No financial relationships to disclose
Laurence Albiges, MD, PhD: Advisory or Consulting or Honoraria, (all paid to Institution): Astellas – BMS – Ipsen – Janssen – Merck - MSD – Novartis - Pfizer – EISAI – Roche (Ongoing)